QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Abstracts on Spinal Cord Stimulation co-authored by Quantify accepted for oral presentation at the 1st joint Congress of the INS European Chapters
The abstracts ”A Swedish Research Database for Spinal Cord Stimulation (SWECOST)” and “Quality of Life and Indirect Cost Outcomes in Patients Treated with Spinal Cord Stimulation Following Spine Surgery” co-authored by Quantify’s Emma Jonsson, Amanda Hansson-Hedblom and Fredrik Borgström have been accepted for oral presentation at the 1st joint Congress of the INS European Chapters, held in Nijmegen, The Netherlands, September 19-22.
Quantify team co-authors paper on cost‑effectiveness of ustekinumab in Crohn’s disease
The paper “Cost‑effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden”, co-authored by Quantify’s Amanda Hansson-Hedblom, Fredrik Borgström, and Linda Karlsson, has been published in Cost Effectiveness and Resource Allocation. See the full article here.
Quantify authors report on access to new medicines in Sweden on behalf of LIF
Connecting to our previous post “1/3 of new medicines are not available to Swedish patients“, the Swedish Association of the Pharmaceutical Industry (LIF) has now published the full report on access to new medicines in Sweden.
A short presentation of the results and the report can be found here.
1/3 of new medicines are not available to Swedish patients
Quantify Research has supported the Swedish Association of the Pharmaceutical Industry (LIF) to re-analyse the EFPIA 2017 Patients W.A.I.T. Indicator for new medicines. We found that about 1/3 of EMA approved medicines are not available in Sweden. Some of these can be replaced with other treatment options, but in other cases Swedish patients may suffer consequences from not having access to the latest medicines available for their disease. For […]